Tuberculosis

nor-NOHA acetate is a selective and reversible Arginase inhibitor. nor-NOHA acetate induces Apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA acetate has anti-leukemic activity. nor-NOHA acetate improves liver ischemia-reperfusion injury. nor-NOHA acetate can used in study of tuberculosis, endothelial dysfunction, immunosuppression and metabolism.

ESAT6 Epitope is a ESAT6 CD4⁺ T cell epitope. ESAT6 Epitope binds to MHC class I molecules with an IC₅₀ value of approximately 180 nM. ESAT6 Epitope has weak immunogenicity. ESAT6 Epitope can be used in studies related to pulmonary tuberculosis.

Isopimaric acid is a coniferous tree defense compound. Isopimaric acid binds to AKT and inhibits mTOR phosphorylation, thereby regulating the AKT/mTOR pathway. Isopimaric acid inhibits oxidative stress, inflammation, microglial migration, apoptosis, autophagic flux, ornithine decarboxylase activity, breast cancer proliferation and metastasis, and fungal spore germination. Isopimaric acid also induces M2 microglial polarization, mitochondrial damage, ROS accumulation, starvation-induced colon cancer cell apoptosis, and breast cancer cell cycle arrest. Isopimaric acid activates potassium channels, regulates sodium channels and calcium channels, reduces myocardial excitability, and improves arrhythmia. Isopimaric acid acts as an oxidative substrate for CYP6BW1/3, down-regulates PINK1/Parkin, and regulates calcium homeostasis, oxidative phosphorylation, EMT, and the Wnt pathway. Isopimaric acid exhibits activity against drug-resistant Staphylococcus aureus, repels feeding, and promotes the growth of rice seedlings. Isopimaric acid is suitable for research related to epilepsy, tumors, drug-resistant bacterial infections, atrial fibrillation, hypertension, hyperlipidemia, pulmonary tuberculosis, etc.

Antitubercular agent-56, a Questiomycin A (HY-N8439) derivative, is a potent and orally active antitubercular agent. Antitubercular agent-56 disrupts mycobacterial envelope integrity by inhibiting FabD (K_d = 9.39 μM; IC₅₀ = 49.60 μM). Antitubercular agent-56 exhibits good intracellular antimycobacterial activity against Mycobacterium tuberculosis (MTB) and drug-resistant MTB both in vitro and in vivo. Antitubercular agent-56 can be used for research on tuberculosis (TB).

BVL3572S, a hydroxamic acid derivative, exhibits potent bactericidal activity against Mycobacterium tuberculosis (Mtb) with a MIC₉₀ of 1.7 µM. BVL3572S inhibits pyridoxal phosphate (PLP)-dependent aminotransferases HisC and AlaA to kill Mtb. BVL3572S can be used for tuberculosis (TB) research.

DL-Cycloserine is an orally active aminotransferase inhibitor. DL-Cycloserine exhibits completely opposite effects on the activity of monoamine oxidase in different tissues. DL-Cycloserine can be used for the research of pulmonary tuberculosis, psychosomatic diseases, and depressive states.

DL-Cycloserine-¹⁵N,d₃ is the deuterium labeled DL-Cycloserine (HY-W008440). DL-Cycloserine is an orally active aminotransferase inhibitor. DL-Cycloserine exhibits completely opposite effects on the activity of monoamine oxidase in different tissues. DL-Cycloserine can be used for the research of pulmonary tuberculosis, psychosomatic diseases, and depressive states.

DL25 is a fungicide with an IC₅₀ of 5.0 μg/mL against Mycobacterium tuberculosis DHQS. DL25 binds with high affinity to mycobacterial targets LysA, LpdA and SecA1. DL25 exhibits broad-spectrum anti-mycobacterial activity against multiple mycobacterial species and shows partial synergy with established anti-tuberculosis drugs. DL25 can be used in studies related to tuberculosis.

Antimycobacterial agent-14 (compound 20s) is an antimycobacterial agent with potent activity against Mycobacterium tuberculosis (M.tb) H37Ra strain with a MIC of 11.37 μM. Antimycobacterial agent-14 can be used for tuberculosis (TB) research.

Antituberculosis agent-17 (compound 21) is a potent and selective antituberculosis agent. Antituberculosis agent-17 displays excellent anti-Tuberculosis (TB) activity against H37Rv, MDR and XDR strains of TB (MIC = 0.2-0.78 μM). Antituberculosis agent-17 exhibits selectivity for Mycobacterium tuberculosis over selected non-TB forming mycobacteria and bacteria. Antituberculosis agent-17 can be used for TB research.